Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Additive Manufactured Scaffolds for Bone Tissue Engineering: Physical Characterization of Thermoplastic Composites with Functional Fillers.
Sinha R, Sanchez A, Camara-Torres M, Uriszar-Aldaca IC, Calore AR, Harings J, Gambardella A, Ciccarelli L, Vanzanella V, Sisani M, Scatto M, Wendelbo R, Perez S, Villanueva S, Matanza A, Patelli A, Grizzuti N, Mota C, Moroni L. Sinha R, et al. Among authors: sisani m. ACS Appl Polym Mater. 2021 Aug 13;3(8):3788-3799. doi: 10.1021/acsapm.1c00363. Epub 2021 Aug 2. ACS Appl Polym Mater. 2021. PMID: 34476399 Free PMC article.
3D additive manufactured composite scaffolds with antibiotic-loaded lamellar fillers for bone infection prevention and tissue regeneration.
Cámara-Torres M, Duarte S, Sinha R, Egizabal A, Álvarez N, Bastianini M, Sisani M, Scopece P, Scatto M, Bonetto A, Marcomini A, Sanchez A, Patelli A, Mota C, Moroni L. Cámara-Torres M, et al. Among authors: sisani m. Bioact Mater. 2020 Oct 15;6(4):1073-1082. doi: 10.1016/j.bioactmat.2020.09.031. eCollection 2021 Apr. Bioact Mater. 2020. PMID: 33102947 Free PMC article.
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Buti S, Olivari A, Masini C, Bimbatti D, Sartori D, Ermacora P, Cattrini C, Vitale MG, Rossi E, Mucciarini C, Rizzo M, Sisani M, Santoni M, Roviello G, Mollica V, Conteduca V, Grillone F, Cinausero M, Prati G, Atzori F, Stellato M, Massari F, Bersanelli M. Buti S, et al. Among authors: sisani m. Ther Adv Urol. 2024 Apr 17;16:17562872241244574. doi: 10.1177/17562872241244574. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 38638242 Free PMC article.
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. Francolini G, et al. Among authors: sisani m. Med Oncol. 2023 Dec 29;41(1):39. doi: 10.1007/s12032-023-02268-3. Med Oncol. 2023. PMID: 38157111 Clinical Trial.
Results of the observational prospective RealFLOT study.
Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L. Giommoni E, et al. Among authors: sisani m. BMC Cancer. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. BMC Cancer. 2021. PMID: 34625033 Free PMC article.
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: sisani m. Ann Oncol. 2016 Feb;27(2):366. doi: 10.1093/annonc/mdv589. Epub 2015 Dec 18. Ann Oncol. 2016. PMID: 26685011 Free article. No abstract available.
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. Bracarda S, et al. Among authors: sisani m. Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26437324
19 results